解可溶 (pro) 因因受体介导的内皮功能障碍
Lachlan G Schofield1, Juyi Zhao2, Yu Wang3
1School of Biomedical Sciences and Pharmacy, College of Health Medicine and Wellbeing, University of Newcastle, Callaghan (Awabakal Country), 2308, New South Wales, Australia; Women's Health Research Program, Hunter Medical Research Institute, New Lambton Heights (Awabakal Country), 2305, New South Wales, Australia.
European journal of pharmacology
|April 5, 2025
概括
PRO20是一种可溶性氨酸受体 (s(P) RR) 的抗体,通过抑制s(P) RR-氨酸II型1受体 (AT1R) 复合体,有效地预防s(P) RR诱导的内皮功能障碍. 这表明PRO20是孕前的潜在治疗方法.
科学领域:
- 生殖生物学 生殖生物学
- 血管生物学 血管生物学
- 内分泌学 在内分泌学.
背景情况:
- 孕前与母亲内皮功能障碍和高血压有关.
- 在预先怀孕的怀孕中观察到可溶性前列宁受体 (s(P) RR) 水平升高.
- 再组合成的s(P) RR导致高血压和血管功能障碍.
研究的目的:
- 为了研究PRO20的作用,一个s(P) RR对抗剂,在s(P) RR诱导的内皮功能障碍.
- 为了检查s(P) RR,PRO20和 ангиотензинII类型1受体 (AT1R) 之间的相互作用.
主要方法:
- 人类子宫微血管内皮细胞 (HUtMECs) 用s(P) RR,PRO20,洛萨坦 (AT1R抗剂) 或阿利斯凯林 (雷宁抑制剂) 进行治疗.
- 内皮功能障碍标志物通过免疫块,qPCR和ELISA进行了评估.
- 用蛋白质结构预测和分子对接来建模s(P) RR-AT1R相互作用.
主要成果:
- PRO20降低了P) RR诱导的mRNA表达的内甲素-1,VCAM-1和ICAM-1.
- PRO20 预防了s(P) RR和血清诱导的内甲素-1 和VCAM-1 的血清预先瘤蛋白质增加.
- 分子建模表明,PRO20会损害s(P) RR-AT1R复合体的形成.
结论:
- 升高的s(P) RR有助于内皮功能障碍,部分通过AT1R.
- PRO20 抑制了 s(P) RR-AT1R 复合物的形成.
- PRO20显示出对孕前和相关疾病的治疗潜力.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
456
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
456
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
406
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
406
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
548
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
548
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
103
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
103